ABAlison Potts Bleakman

Alison Potts Bleakman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alison Potts Bleakman has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial

    by Millie Long, David Laharie, Gerhard Rogler, Seyedehsan Navabi, Aisha Vadhariya, William J Eastman, Tian Tian, Alison Potts Bleakman, Alessandro Armuzzi

    Background: Mirikizumab, an anti-interleukin-23p19 monoclonal antibody approved for ulcerative colitis (UC) and Crohn’s disease, was evaluated in LUCENT-URGE (NCT05767021), a phase 3b, open-label study assessing its effect on bowel urgency (BU) through week (W)28 in adults with moderately-to-severely active UC, using novel BU measures and validated quality of life (QoL) instruments. Methods: Patients with UC experiencing BU (baseline severity ≥3 on the urgency numeric rating scale [UNRS]) received 300 mg mirikizumab intravenously at W0, W4, and W8, then 200 mg subcutaneously at W12 and every 4 weeks up to W24. Improvements in QoL and patient-reported outcomes were assessed from baseline to W12 and W28. Results: Among 172 patients, 58.1% achieved clinically meaningful improvement (≥3-point reduction in UNRS), and 37.8% reached BU remission (rounded UNRS ≤ 1) by W28. Inflammatory Bowel Disease Questionnaire (IBDQ) scores improved by 56.4 points, with 52.3% of patients achieving IBDQ-remission (IBDQ ≥ 170) and 65.7% achieving IBDQ-response (≥16-point increase) at W28. Absorbent product use for BU dropped from 55.1% at baseline to 29.6% at W28. Patients reporting no sexual activity avoidance (SAA) due to UC symptoms rose from 21.1% to 51.4%. Activity impairment, Wexner Incontinence Score, and anxiety symptoms also showed improvements. Conclusion: The majority of mirikizumab-treated patients achieved clinically meaningful BU improvement over 28 weeks. In addition to QoL improvement, patients experienced reduced disruption of daily activities, with meaningful reductions in SAA and use of protective aids due to BU. Achieving BU remission or clinically meaningful improvement with mirikizumab was associated with improvements in patients’ relevant UC symptoms and overall QoL.

  • Open Access

    Genital Psoriasis: An Updated Review of Diagnosis and Management for Healthcare Providers

    by Lyn C. Guenther, Jennifer C. Cather, Melinda J. Gooderham, Brian Kirby, Joseph F. Merola, Kim Meeuwis, Alyssa Garrelts, Alison Potts Bleakman, Emily Edson-Heredia, Russel T. Burge

    Psoriasis is a chronic inflammatory skin condition that may affect all body areas, including the genital area. Genital psoriasis occurs in up to two‐thirds of patients with psoriasis at some point during their lifetime but is often overlooked. Genital psoriasis is associated with severe impairment in sexual health and quality of life. Despite the prevalence of genital psoriasis, there is often a lack of communication between patients and healthcare providers, resulting in underdiagnosis and under‐reporting of genital psoriasis along with lack of treatment or inappropriate self‐treatment. There are only a limited number of interventional clinical trials evaluating the efficacy and safety of treatments. The current initial treatment recommendations include topical corticosteroids, vitamin D analogues, phosphodiesterase‐4 (PDE4) inhibitors, and topical calcineurin inhibitors. Systemic and biologic therapies are reserved for unresponsive and/or widespread disease. Moreover, the genital skin is susceptible to increased absorption and adverse effects from current topical therapies, making treatment of genital psoriasis challenging. Patients with genital psoriasis may present to clinicians with varying expertise in the diagnosis and management of genital psoriasis. To improve management of patients with genital psoriasis, there is an unmet need for sharing of expertise and partnership between nondermatology healthcare providers and dermatologists.

  • Open Access

    Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers

    by Marla Dubinsky, Alison Potts Bleakman, Stephan Vavricka, Simon Travis, Vipul Jairath, Remo Panaccione, María Chaparro, Bénédicte Caron, Deborah A. Fisher, Richard Moses, et al.

    Bowel urgency (BU) is a prevalent and highly burdensome symptom among patients with inflammatory bowel disease. While BU is now recognized as a key symptom of ulcerative colitis, in the case of Crohn's disease (CD), it is often under-recognized by healthcare providers (HCPs) and inadequately captured in clinical assessments. Reported in up to 96% of patients with CD, BU can significantly impair quality of life, contributing to anxiety, social withdrawal, and reduced daily functioning. Despite its frequency and impact, BU is excluded from widely used CD activity indices and is infrequently included in clinical trial end points. An important challenge in the management of CD is the differing perceptions between patients and HCPs regarding the impact and importance of BU. This disconnect between patients and HCPs may lead to gaps in treatment and unmet patient needs. This narrative review synthesizes recent evidence on the prevalence, clinical significance, and underlying mechanisms of BU in CD. We also examine its impact on quality of life, evaluate current assessment tools, and highlight therapeutic approaches and gaps in HCP-patient communication. Greater awareness and systematic evaluation of BU as a multidimensional symptom of CD are critical for optimizing care and aligning clinical management with patient priorities.


  • Open Access

    Impact of moderate-to-severe ulcerative colitis and Crohn’s disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey

    by Marla C. Dubinsky, Alison Potts Bleakman, Stefan Schreiber, David T. Rubin, Remo Panaccione, Toshifumi Hibi, Cem Kayhan, Theresa Hunter Gibble, Eoin J. Flynn, Angelo D. Favia, et al.

    Ulcerative colitis (UC) and Crohn's disease (CD) negatively affect patients' quality of life, and their impact on patients' sexual health is rarely addressed. This study assessed the impact of moderate-to-severe UC and CD on sexual activity using United States (US) and European data from the Communicating Needs and Features of IBD Experiences (CONFIDE) survey. Online, quantitative, cross-sectional surveys were conducted among patients with moderate-to-severe UC or CD and health care professionals (HCPs). Moderate-to-severe UC or CD were defined using criteria based on previous treatment, steroid use, and/or hospitalization. The surveys were developed with input from HCPs and patient advisors and included questions on demographics, UC- or CD-related symptoms, and the impact of UC or CD on sexual health. Patients were asked whether they had avoided/decreased sexual activity in the past 3 months and their UC- or CD-related reasons. Patients and HCPs rated levels of impact of UC or CD on sex life/sexual intimacy and patients rated how bowel urgency interferes with their relationship with spouse/partner. Additionally, questions assessing the psychosocial health of patients and identifying gaps and barriers in HCP-patient communication were also included. Descriptive statistics were used to summarize the data. Surveys were completed by 200 US and 556 European patients with UC and 215 US and 547 European patients with CD. Of these, most US (UC: 63%, CD: 69%) and European (UC: 53%, CD: 56%) patients reported avoiding or decreasing sexual activity due to UC or CD in the past 3 months; however, the proportion was significantly greater among US patients (P < 0.05). Among patients with UC, significantly greater proportion of female patients reported altered sexual activity due to their disease. A similar proportion of male and female patients with CD reported impaired sexual activity. Most common UC-related reasons for avoidance of sexual activity were bowel urgency among US patients and fear of faecal seepage among European patients. Among patients with CD, the most common reason was fear of bowel urgency-related accidents in both US and European patients. Patients reported a negative impact of bowel urgency on their relationship with spouse/partner. In US and Europe, most patients reported avoiding or decreasing sexual activity due to moderate-to-severe UC or CD, with bowel urgency and bowel urgency-related accidents being common reasons. Assessing and addressing sexual health in routine clinical care should be considered when treating UC and CD.


  • Open Access

    Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study

    by Toshifumi Hibi, Taku Kobayashi, Masaru Tanaka, Satoshi Osaga, Alison J. Potts Bleakman, Theresa Hunter Gibble, Marijana Nedeljkovic Protic, Isabel Redondo, Koji Matsuo, Tadakazu Hisamatsu

    Introduction The global Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study aimed to evaluate the impact of ulcerative colitis (UC)- and Crohn’s disease (CD)-related symptoms on patients’ lives and elucidate communication gaps between patients and health care professionals (HCPs). We report the findings from the study in patients with UC or CD and HCPs in Japan. Methods Online, quantitative, cross-sectional surveys were conducted in Japan for patients with moderate-to-severe UC or CD and HCPs responsible for the care of patients with UC and/or CD. Subgroup analyses based on disease activity were conducted using the Manitoba Inflammatory Bowel Disease Index. Data were described using descriptive statistics. Results Surveys were completed by 124 patients with UC, 99 patients with CD, and 100 HCPs in Japan. Differences were noted in the most common patient-reported symptoms experienced in the month prior to survey completion between patients with UC and CD (diarrhea [45.2% UC, 68.7% CD], flatulence [34.7% UC, 32.3% CD], increased stool frequency [32.3% UC, 43.4% CD], bowel urgency [BU; 25.0% UC, 32.3% CD], and fatigue [36.4% CD]). More patients with active disease than inactive disease reported these symptoms. BU and BU-related accidents were among the symptoms ranked as most impactful by patients with UC and CD. HCP-perceived symptoms with the greatest impact on patients were diarrhea and blood in stool. Findings in the Japanese cohort of CONFIDE were generally consistent with those in the United States (US)/European cohorts. The percentage of patients reporting BU as the symptom with the greatest impact was higher in the US/European cohorts than in the Japanese cohort, potentially as a result of differences in baseline characteristics and social environments such as toilet facilities. Conclusion BU is an impactful symptom among Japanese patients with UC and CD and should be considered by HCPs during treatment of these conditions.


  • Open Access

    Rectal Urgency Among Patients With Ulcerative Colitis or Crohn’s Disease: Analyses from a Global Survey

    by Christina Ha, April N Naegeli, Rina Lukanova, Mingyang Shan, Rosie Wild, Fritha Hennessy, Uma Jyothi Kommoju, Alison Potts Bleakman, Theresa Hunter Gibble

    Background: Rectal urgency is a common but under-reported inflammatory bowel disease (IBD) symptom. The present study assessed the prevalence of rectal urgency and its association with disease activity and patient-reported outcomes (PROs) among patients with ulcerative colitis (UC) or Crohn’s disease (CD) in a real-world setting. Methods: Data were drawn from the 2017–2018 Adelphi IBD Disease Specific Programme™, a multi-center, point-in-time survey of gastroenterologists and consulting adult patients with UC or CD in France, Germany, Italy, Spain, the United Kingdom, and the United States. Gastroenterologists completed patient record forms and patients completed self-reported forms. Analyses were conducted separately for patients with UC or CD. Patient demographics, clinical characteristics, disease activity, symptoms, and PROs were compared between patients with and without rectal urgency. Results: In total, 1057 patients with UC and 1228 patients with CD were included. Rectal urgency was reported in 20.2% of patients with UC and 16.4% with CD. Patients with rectal urgency were more likely to have moderate or severe disease (UC or CD: P < .0001), higher mean Mayo score (UC: P < .0001), higher mean Crohn’s Disease Activity Index score (CD: P < .0001), lower Short IBD Questionnaire scores (UC or CD: P < .0001), and higher work impairment (UC: P < .0001; CD: P = .0001) than patients without rectal urgency. Conclusions: Rectal urgency is a common symptom associated with high disease activity, decreased work productivity, and worse quality of life. Further studies are needed to include rectal urgency assessment in routine clinical practice to better gauge disease activity in patients with UC or CD.


  • Open Access

    Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions

    by Marla Dubinsky, Alison Potts Bleakman, Remo Panaccione, Toshifumi Hibi, Stefan Schreiber, David Rubin, Axel Dignass, Isabel Redondo, Theresa Hunter Gibble, Cem Kayhan, et al.

    Bowel urgency (BU), the sudden or immediate need for a bowel movement, is one of the most common and disruptive symptoms experienced by patients with ulcerative colitis (UC). Distinct from the separate symptom of increased stool frequency, BU has a substantial negative impact on quality of life and psychosocial functioning. Among patients with UC, BU is one of the top reasons for treatment dissatisfaction and one of the symptoms patients most want improved. Patients may not discuss BU often due to embarrassment, and healthcare providers may not address the symptom adequately due to the lack of awareness of validated tools and/or knowledge of the importance of assessing BU. The mechanism of BU in UC is multifactorial and includes inflammatory changes in the rectum that may be linked to hypersensitivity and reduced compliance of the rectum. Responsive and reliable patient-reported outcome measures of BU are needed to provide evidence of treatment benefits in clinical trials and facilitate communication in clinical practice. This review discusses the pathophysiology and clinical importance of BU in UC and its impact on the quality of life and psychosocial functioning. Patient-reported outcome measures developed to assess the severity of BU in UC are discussed alongside overviews of treatment options and clinical guidelines. Implications for the future management of UC from the perspective of BU are also explored.